Company No:
Contents
| Directors | Mary Assimakopoulos |
| Mark Angus Jeffery |
| Registered office | 2nd Floor 168 Shoreditch High Street |
| London | |
| United Kingdom |
| Company number | 10522796 (England and Wales) |
| Accountant | Kreston Reeves LLP |
| 2nd Floor | |
| 168 Shoreditch High Street | |
| London | |
| E1 6RA |
| Note | 2024 | 2023 | ||
| £ | £ | |||
| Fixed assets | ||||
| Investments | 3 |
|
|
|
| 11,161,182 | 10,148,799 | |||
| Current assets | ||||
| Debtors | 4 |
|
|
|
| Cash at bank and in hand |
|
|
||
| 1,811,597 | 1,706,269 | |||
| Creditors: amounts falling due within one year | 5 | (
|
(
|
|
| Net current liabilities | (9,949,270) | (10,054,598) | ||
| Total assets less current liabilities | 1,211,912 | 94,201 | ||
| Net assets |
|
|
||
| Capital and reserves | ||||
| Called-up share capital | 6 |
|
|
|
| Profit and loss account |
|
|
||
| Total shareholders' funds |
|
|
Directors' responsibilities:
The financial statements of MAMJ Holdings Limited (registered number:
|
Mark Angus Jeffery
Director |
The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial year, unless otherwise stated.
MAMJ Holdings Limited (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the Company's registered office is 2nd Floor 168 Shoreditch High Street, London, United Kingdom.
The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.
The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.
The Company's functional and presentational currency is GBP.
Transactions and balances
Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.
At each period end foreign currency monetary items are translated using the closing rate. Nonmonetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.
Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss except when deferred in other comprehensive income as qualifying cash flow hedges.
Foreign exchange gains and losses that relate to borrowings and cash and cash equivalents are presented in the Statement of income and retained earnings within 'finance income or costs'. All other foreign exchange gains and losses are presented in profit or loss within 'other operating income'.
Finance costs are charged to the Profit and Loss Account over the term of the debt using the effective interest method so the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.
Investments in listed company shares are remeasured to market value at each balance sheet date. Gains and losses on remeasurement are recognised in profit or loss for the period.
The Company only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investments in ordinary shares.
| 2024 | 2023 | ||
| Number | Number | ||
| Employees other than the directors, who did not receive any remuneration |
|
|
| Listed investments | Other investments | Total | |||
| £ | £ | £ | |||
| Cost or valuation before impairment | |||||
| At 01 January 2024 |
|
|
|
||
| Additions |
|
|
|
||
| Disposals | (
|
|
(
|
||
| Movement in fair value |
|
|
|
||
| Net cash invested/(withdrawn) |
|
|
|
||
| At 31 December 2024 |
|
(
|
|
||
| Carrying value at 31 December 2024 |
|
(
|
|
||
| Carrying value at 31 December 2023 |
|
|
|
| 2024 | 2023 | ||
| £ | £ | ||
| Other debtors |
|
|
| 2024 | 2023 | ||
| £ | £ | ||
| Amounts owed to directors |
|
|
|
| Accruals |
|
|
|
|
|
|
| 2024 | 2023 | ||
| £ | £ | ||
| Allotted, called-up and fully-paid | |||
|
|
|
|
During the year, the company paid expenses totalling £18,575 (2023: £16,528) on behalf of Research Partnership Investments France. At the year end, the company was owed £1,713,007 (2023: £1,694,432) by Research Partnership Investments France.
At the balance sheet date, a balance of £5,877,609 was owed to Mark Jeffery, a director of the company.
At the balance sheet date, a balance of £5,877,608 was owed to Mary Assimakopoulos , a director of the company.
The Company considers its ultimate control relationship to be M Assimakopoulos and M A Jeffery, as directors and ultimate shareholders. Each director holds 50% of the shareholding in the company.